Regeneron Pharmaceuticals

REGN

Market cap $69.9B

REGN Hedge Fund Activity: Q1 2026 in Review

1,393 of the 8,131 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2026, worth a combined $69.8B — down 1.3% from $70.7B a quarter earlier.

Buyers outnumbered sellers: 134 funds opened new REGN positions and 100 closed out — a net gain of 34 holders — while 574 added to existing stakes and 462 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $898M. The largest seller was Fidelity Investments, cutting an estimated $614M.

• 1,393 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2026, up from 1,386 in Q4 2025.
• Funds reported $69.8B of Regeneron Pharmaceuticals stock for Q1 2026, down 1.3% quarter-over-quarter.
• 134 funds opened new Regeneron Pharmaceuticals positions in Q1 2026 and 100 closed out, a net change of +34 holders.
• The largest Regeneron Pharmaceuticals buyer in Q1 2026 was Wellington Management Group, an estimated $898M added.
• The largest Regeneron Pharmaceuticals seller in Q1 2026 was Fidelity Investments, an estimated $614M sold.

Based on aggregated 13F filings for Q1 2026.